Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Favorable therapeutic response with an antiretroviral salvage regimen in an HIV-1-positive subject infected with a CRF11-cpx virus.

Tau P, Mancon A, Mileto D, Di Nardo Stuppino S, Bottani G, Gismondo MR, Galli M, Micheli V, Rusconi S.

AIDS Res Hum Retroviruses. 2014 May;30(5):480-3. doi: 10.1089/AID.2013.0264. Epub 2013 Dec 31.

PMID:
24279648
2.

Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.

Passaes CP, Guimarães ML, Cardoso SW, Pilotto JH, Veloso V, Grinsztejn B, Morgado MG.

J Med Virol. 2012 Dec;84(12):1869-75. doi: 10.1002/jmv.23409.

PMID:
23080489
3.

Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.

Aghokeng AF, Kouanfack C, Eymard-Duvernay S, Butel C, Edoul GE, Laurent C, Koulla-Shiro S, Delaporte E, Mpoudi-Ngole E, Peeters M.

J Int AIDS Soc. 2013 Jan 31;16:18004. doi: 10.7448/IAS.16.1.18004.

4.

Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.

Frange P, Briand N, Avettand-fenoel V, Veber F, Moshous D, Mahlaoui N, Rouzioux C, Blanche S, Chaix ML.

Pediatr Infect Dis J. 2011 Aug;30(8):684-8. doi: 10.1097/INF.0b013e31821752d6.

PMID:
21427626
5.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
6.

Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.

de Mulder M, Yebra G, Martín L, Prieto L, Mellado MJ, Rojo P, Muñoz-Fernández MÁ, Jiménez de Ory S, Ramos JT, Holguín A; Madrid cohort of HIV-infected children.

J Antimicrob Chemother. 2011 Oct;66(10):2362-71. doi: 10.1093/jac/dkr305. Epub 2011 Aug 2.

7.

48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.

Patel DA, Snedecor SJ, Tang WY, Sudharshan L, Lim JW, Cuffe R, Pulgar S, Gilchrist KA, Camejo RR, Stephens J, Nichols G.

PLoS One. 2014 Sep 4;9(9):e105653. doi: 10.1371/journal.pone.0105653. eCollection 2014. Review.

9.

HIV-1 subtype B/B' and baseline drug resistance mutation are associated with virologic failure: a multicenter cohort study in China.

Li Y, Gu L, Han Y, Xie J, Wang H, Lv W, Song X, Li Y, Iwamoto A, Ishida T, Li T; CACT0810 group.

J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):289-97. doi: 10.1097/QAI.0000000000000473.

PMID:
25501612
10.

Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.

Maggiolo F, Callegaro A, Arici C, Quinzan G, Gregis G, Ripamonti D, Tebaldi A, Goglio A, Suter F.

Antivir Ther. 2003 Apr;8(2):121-6.

PMID:
12741624
11.

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G; SINGLE Investigators.

N Engl J Med. 2013 Nov 7;369(19):1807-18. doi: 10.1056/NEJMoa1215541.

12.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;6:CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
13.
14.

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.

Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, Schneider V, Ferre V, Izopet J, Si-Mohamed A, Maillard A, Henquell C, Desbois D, Lazrek M, Signori-Schmuck A, Rogez S, Yerly S, Trabaud MA, Plantier JC, Fourati S, Houssaini A, Masquelier B, Calvez V, Flandre P; ANRS AC11 Resistance Group.

Int J Antimicrob Agents. 2013 Jul;42(1):42-7. doi: 10.1016/j.ijantimicag.2013.02.016. Epub 2013 Apr 4.

PMID:
23562640
15.

Prevalence and patterns of drug-resistance mutations among HIV-1 patients infected with CRF07_BC strains in Sichuan province, China.

Su L, Zhou X, Yuan D, Yang H, Wei D, Qin G, Liang S.

Virol Sin. 2014 Aug;29(4):237-41. doi: 10.1007/s12250-014-3487-x. Epub 2014 Aug 8.

PMID:
25160759
16.

In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.

Souza Cavalcanti J, Minhoto Lança A, de Paula Ferreira JL, da Eira M, de Souza Dantas DS, de Macedo Brígido LF.

Antiviral Res. 2012 Jul;95(1):9-11. doi: 10.1016/j.antiviral.2012.04.007. Epub 2012 May 4.

17.

Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.

Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick LM, Podsadecki TJ, Nilius AM.

HIV Clin Trials. 2011 Sep-Oct;12(5):255-67. doi: 10.1310/hct1205-255.

PMID:
22180523
19.

[Molecular characterization of complex recombinant HIV-1 CRF06_cpx subtype detected in Turkey].

Sayan M, Kaptan F, Ormen B, Türker N.

Mikrobiyol Bul. 2014 Jan;48(1):160-7. Turkish.

20.

The use of efavirenz as a part of late rescue antiretroviral treatment.

Manfredi R, Rizzo E, Calza L, Chiodo F.

HIV Clin Trials. 2001 Sep-Oct;2(5):413-20.

PMID:
11673816
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk